Alternative Data for Kazia Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 14,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 15 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,749 | Sign up | Sign up | Sign up |
| X Followers | 935 | Sign up | Sign up | Sign up |
| X Mentions | 3 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 273 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 14 | Sign up | Sign up | Sign up |
About Kazia Therapeutics
Kazia Therapeutics KZIA is an Australia-based clinical-stage company focused on developing drugs targeting oncology indications.
| Price | $7.49 |
| Target Price | Sign up |
| Volume | 66,430 |
| Market Cap | $85M |
| Year Range | $5 - $15.72 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast CancerJanuary 26 - Yahoo |
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
 |
12 Health Care Stocks Moving In Wednesday's Intraday SessionMarch 3 - Benzinga |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | 0 | 0 | |
| Q2 '25 | 0 | 0 | 0 | 0 | 0 | |
| Q4 '24 | 22,000 | 0 | 22,000 | -10M | -8.4M | |
| Q3 '24 | 2.5M | 0 | 2.5M | -18M | -19M | -31.220 |
| Q2 '24 | 0 | 0 | 0 | 0 | 0 | 0.000 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Kazia Therapeutics (KZIA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews & linkedin employees.
FAQ - Kazia Therapeutics
The Market Cap of Kazia Therapeutics is $85M.
Currently, the price of one share of Kazia Therapeutics stock is $7.49.
The KZIA stock price chart above provides a comprehensive visual representation of Kazia Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Kazia Therapeutics shares. Our platform offers an up-to-date KZIA stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Kazia Therapeutics (KZIA) does not offer dividends to its shareholders. Investors interested in Kazia Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Kazia Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
